David A. Alagpulinsa, PhD
Assistant ProfessorCards
Appointments
Contact Info
About
Titles
Assistant Professor
Biography
David is an Assistant Professor of Comparative and Cardiovascular Medicine. His doctoral studies in Interdisciplinary Biomedical Sciences at the University of Arkansas for Medical Scinces in Little Rock, Arkansas, focused on defining and exploiting the mechanisms that maintain genome integrity in multiple myeloma, a hematologic malignancy of B lymphocytes. He completed a postdoctoral training at the Massachusetts General Hospital and Harvard Medical School in Boston, developing strategies to immunoprotect endogenous and transplanted islets to treat type 1 diabetes without systemic immunosuppression. David joined the Yale Center for Molecular and Systems Metabolism and Department of Comparative Medicine at Yale as an Assistant Professor in 2023 to establish the AlagsLab. Research in the AlagsLab integrates knowledge from genetics, developmental and molecular biology, immunology, biomedical engineering, and statistical and computational biology to understand complex traits and diseases, including hematopoiesis, T1D, and cardiovascular disease.
Appointments
Comparative Medicine
Assistant ProfessorPrimaryCardiovascular Medicine
Assistant ProfessorSecondary
Other Departments & Organizations
- Alagpulinsa Laboratory
- Cardiovascular Medicine
- Comparative Medicine
- Internal Medicine
- Janeway Society
- Molecular Medicine, Pharmacology, and Physiology
- Program in Translational Biomedicine (PTB)
- Vascular Biology and Therapeutics Program
- Yale Center for Molecular and Systems Metabolism (YMSM)
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
Education & Training
- Instructor
- Massachusetts General Hospital & Harvard Medical School (2023)
- Postdoc
- Massachusetts General Hospital & Harvard Medical School (2021)
- PhD
- University of Arkansas for Medical Sciences (2015)
Research
Overview
Medical Subject Headings (MeSH)
- View Lab Website
Alagpulinsa Lab
Research at a Glance
Publications Timeline
Publications
2024
Genetic relations between leukocyte counts, type 1 diabetes, and coronary artery disease
Adebekun J, Nadig A, Saarah P, Asgari S, Kachuri L, and Alagpulinsa DA*. Genetic relations between leukocyte counts, type 1 diabetes, and coronary artery disease. medRxiv, 2024: p. 2024.04.01.24305155.Peer-Reviewed Original Research
2023
Plasma osteopontin relates to myocardial fibrosis and steatosis and to immune activation among women with HIV.
Robinson JA, Toribio M, Quinaglia T, Awadalla M, Talathi R, Durbin CG, Alhallak I, Alagpulinsa DA, Fourman LT, Suero-Abreu GA, Nelson MD, Stanley TL, Longenecker CT, Szczepaniak LS, Jerosch-Herold M, Neilan TG, Zanni MV, Burdo TH. Plasma osteopontin relates to myocardial fibrosis and steatosis and to immune activation among women with HIV. AIDS 2023, 37: 305-310. PMID: 36541642, DOI: 10.1097/QAD.0000000000003417.Peer-Reviewed Original Research
2022
Advances in understanding the molecular basis of clonal hematopoiesis.
Alagpulinsa DA, Toribio MP, Alhallak I, Shmookler Reis RJ. Advances in understanding the molecular basis of clonal hematopoiesis. Trends Mol Med 2022, 28: 360-377. PMID: 35341686, DOI: 10.1016/j.molmed.2022.03.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Metabolomic and transcriptomic analyses of the anti-rheumatoid arthritis potential of xylopic acid in a bioinspired lipoprotein nanoformulation.
Alolga RN, Opoku-Damoah Y, Alagpulinsa DA, Huang FQ, Ma G, Chavez Leon MASC, Kudzai C, Yin X, Ding Y. Metabolomic and transcriptomic analyses of the anti-rheumatoid arthritis potential of xylopic acid in a bioinspired lipoprotein nanoformulation. Biomaterials 2021, 268: 120482. PMID: 33307367, DOI: 10.1016/j.biomaterials.2020.120482.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Genomic Instability in Multiple Myeloma.
Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ. Genomic Instability in Multiple Myeloma. Trends Cancer 2020, 6: 858-873. PMID: 32487486, DOI: 10.1016/j.trecan.2020.05.006.Peer-Reviewed Original Research
2019
Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma.
Alagpulinsa D, Kumar S, Talluri S, Nanjappa P, Buon L, Chakraborty C, Samur M, Szalat R, Shammas M, Munshi N. Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Advances 2019, 3: 3968-3972. PMID: 31805191, PMCID: PMC6963244, DOI: 10.1182/bloodadvances.2019000181.Peer-Reviewed Original ResearchCitationsAltmetricAlginate-microencapsulation of human stem cell-derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression.
Alagpulinsa DA, Cao JJL, Driscoll RK, Sîrbulescu RF, Penson MFE, Sremac M, Engquist EN, Brauns TA, Markmann JF, Melton DA, Poznansky MC. Alginate-microencapsulation of human stem cell-derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression. Am J Transplant 2019, 19: 1930-1940. PMID: 30748094, DOI: 10.1111/ajt.15308.Peer-Reviewed Original ResearchHarnessing CXCL12 signaling to protect and preserve functional β-cell mass and for cell replacement in type 1 diabetes.
Alagpulinsa DA, Cao JJL, Sobell D, Poznansky MC. Harnessing CXCL12 signaling to protect and preserve functional β-cell mass and for cell replacement in type 1 diabetes. Pharmacol Ther 2019, 193: 63-74. PMID: 30149101, DOI: 10.1016/j.pharmthera.2018.08.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2016
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Mol Cancer Ther 2016, 15: 241-50. PMID: 26719576, DOI: 10.1158/1535-7163.MCT-15-0660.Peer-Reviewed Original Research
Academic Achievements and Community Involvement
activity National Institutes of Health HAI Study Section
Peer Review Groups and Grant Study SectionsAd-hoc reviewerDetails06/15/2023 - Presentactivity Haematologica; American Journal of Transplantation; Trends in Molecular Medicine; Pharmacology & Therapeutics; Frontiers in Cell and Developmental Biology; The FASEB Journal; etc.
Journal ServiceReviewerDetails07/01/2019 - Presenthonor Keystone Fellow
International AwardKeystone SymposiaDetails01/01/2023honor JDRF Diversifying Diabetes Research Talent in Academia Award
National AwardJuvenile Diabetes Research FoundationDetails09/01/2022honor MGH Scientific Advisory Committee on Research Poster of Distinction Award
Other AwardMassachusetts General HosptialDetails04/07/2021
Links & Media
News
Related Links
Get In Touch
Contacts
Locations
Sterling Hall of Medicine
Lab
333 Cedar Street
New Haven, CT 06510